- Moving PSE to Rx-only in Mo. lacks fiscal sense
- Shire files lawsuit against Watson over Adderall XR
- New alliance will crack down on adulterated products touting dietary supplement claims
- Study: Amphetamine use could pose Parkinson's disease risk
- Adherence among chronic disease patients can lead to big savings
PHILADELPHIA — The Food and Drug Administration has approved an attention deficit hyperactivity disorder drug for use in adolescents.
British drug maker Shire announced Monday the approval of Vyvanse (lisdexamfetamine dimesylate) capsules for patients aged 13 to 17. The drug was already approved for children ages 6 years to 12 years and adults.
“This adolescent indication for Vyvanse is good news for kids in this age group diagnosed with ADHD and their caregivers as it offers an additional treatment option to help them manage their symptoms,” Shire SVP ADHD business Mike Yasick said in a statement. “The approval of Vyvanse for children and adults — and now for adolescents — underscores Shire’s commitment to helping ADHD patients and their families.”